Oct 29, 2018

Republicans and the pharmaceutical industry grow apart

President Trump and HHS Secretary Alex Azar. Photo: Chip Somodevilla via Getty Images

Remember when Republicans and the pharmaceutical industry were friends? The pharmaceutical industry does.

Between the lines: Republicans on Capitol Hill barely made a peep last week after the Trump administration rolled out a drug-pricing plan that arguably goes further than the Obama administration ever attempted. This is pharma's second notable setback in just a few months. It was also caught off guard by a Medicare change in a recent spending bill, and failed to persuade lawmakers to reverse that policy in their opioids legislation.

  • The drug industry was "blindsided" by last week's proposal, which was far more aggressive than anything they had expected to see from a Republican administration, my colleague Jonathan Swan and I reported this weekend.
  • "It's a totally new day when it comes to how congressional Republicans message this," a pharmaceutical industry lobbyist told Axios of last week's proposal. "This used to be kind of off limits, and it's definitely not now. And not only is it not off limits, it's kind of popular for them to talk about."

The big picture: Pharma has suffered very close to zero political losses for the past several years, thanks in part to strong lobbying and aggressive campaign contributions, which have tended to favor Republicans.

  • Pharma industry PACs have given almost $9 million to Republican candidates this cycle, according to the Center for Responsive Politics, on top of $11 million in 2016 and $9 million in 2014.

Is the romance over? Not necessarily, the industry lobbyist said — Republicans are still a better bet for pharma than increasingly progressive Democrats.

  • A lot will depend on whether Trump's plan actually comes to fruition. The lobbyist said Republicans will likely say some of it needs to work its way through Congress — where it's likely to die — even if they didn't say much on the merits last week.

The bottom line: “The real fear is, what else is to come?" the lobbyist said. "If this is where we are 2 weeks before the election, and the House actually does flip, what are we going to see next year?”

Go deeper

42 mins ago - Technology

The slippery slope of protest surveillance

Illustration: Aïda Amer/Axios

President Trump's call to treat antifa supporters like terrorists could be a green light for high-tech surveillance of dissidents.

Why it matters: It's unlikely the Trump administration can designate antifa as a terrorist group in any legally meaningful way, but the declaration gives law enforcement tacit approval to use a plethora of tech tools to monitor protesters and left-leaning activists.

The biggest crisis since 1968

Illustration: Aïda Amer/Axios. Photo: Bettmann/Contributor

The year 1968 has been on a lot of people’s minds lately — another year of protests, violence and upheaval that seemed to be tearing the nation apart.

Yes, but: This crisis also has moments we’ve never seen before — and some historians and experts say the differences suggest that 2020 doesn't compare well at all.

SoftBank to launch $100M fund backing companies led by people of color

Illustration: Aïda Amer/Axios

SoftBank COO Marcelo Claure said in a letter to employees early Wednesday that the firm will create a $100 million fund that "will only invest in companies led by founders and entrepreneurs of color."

Why it matters: The Opportunity Growth Fund is one of the first to put significant capital behind companies' statements of empathy and outrage in response to protests over systemic racism in the U.S. typified by the killings of George Floyd, Breonna Taylor and other African Americans by police.